Standaert DG - Search Results

1

Parkinson's disease, primates, and gene therapy: vive la différence?

Lewis TB, Standaert DG. Lewis TB, et al. Among authors: standaert dg. Mov Disord. 2011 Jan;26(1):2-3. doi: 10.1002/mds.23544. Epub 2010 Dec 17. Mov Disord. 2011. PMID: 21322013 Free PMC article. No abstract available.

2

Design of clinical trials of gene therapy in Parkinson disease.

Lewis TB, Standaert DG. Lewis TB, et al. Among authors: standaert dg. Exp Neurol. 2008 Jan;209(1):41-7. doi: 10.1016/j.expneurol.2007.08.012. Epub 2007 Aug 31. Exp Neurol. 2008. PMID: 17920590 Review.

3

Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy.

Lewis TB, Glasgow JN, Glandon AM, Curiel DT, Standaert DG. Lewis TB, et al. Among authors: standaert dg. PLoS One. 2010 Sep 17;5(9):e12672. doi: 10.1371/journal.pone.0012672. PLoS One. 2010. PMID: 20862245 Free PMC article.

4

Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT. Lewis TB, et al. Among authors: standaert dg. Viruses. 2014 Aug 21;6(8):3293-310. doi: 10.3390/v6083293. Viruses. 2014. PMID: 25196484 Free PMC article.

5

Metabolomics and the search for biomarkers in Parkinson's disease.

Amara AW, Standaert DG. Amara AW, et al. Among authors: standaert dg. Mov Disord. 2013 Oct;28(12):1620-1. doi: 10.1002/mds.25644. Epub 2013 Sep 18. Mov Disord. 2013. PMID: 24105981 Free PMC article. No abstract available.

6

Monocytes and Parkinson's disease: invaders from outside?

Harms AS, Standaert DG. Harms AS, et al. Among authors: standaert dg. Mov Disord. 2014 Sep;29(10):1242. doi: 10.1002/mds.25993. Epub 2014 Aug 14. Mov Disord. 2014. PMID: 25124371 No abstract available.

7

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Fernandez HH, et al. Among authors: standaert dg. Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24. Mov Disord. 2015. PMID: 25545465 Free PMC article. Clinical Trial.

8

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.

Fernandez HH, Standaert DG, Chatamra K, Benesh JA. Fernandez HH, et al. Among authors: standaert dg. Mov Disord. 2015 Sep;30(10):1435-6. doi: 10.1002/mds.26316. Epub 2015 Jul 16. Mov Disord. 2015. PMID: 26179940 Free PMC article. No abstract available.

9

Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.

Calabresi P, Standaert DG, Chiasserini D, Parnetti L. Calabresi P, et al. Among authors: standaert dg. Mov Disord. 2016 Jun;31(6):769-70. doi: 10.1002/mds.26683. Mov Disord. 2016. PMID: 27245116 No abstract available.

10

SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.

Figge DA, Standaert DG. Figge DA, et al. Among authors: standaert dg. Mov Disord. 2016 Oct;31(10):1479. doi: 10.1002/mds.26747. Mov Disord. 2016. PMID: 27501414 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

282 results

Search Page